Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy
Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni<sup>®</sup>) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin. This treatment had low cure rates for hepatitis C virus and was teratogenic and therefore avoided in pregnant patients. Ve...
Furkejuvvon:
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2024-06-01
|
| Ráidu: | Pathogens |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2076-0817/13/6/508 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|